<DOC>
	<DOCNO>NCT00280683</DOCNO>
	<brief_summary>Nitric oxide important marker airway inflammation asthma . Nitric oxide may protective role patient moderate severe asthma . The investigator believe natural amino acid , L-arginine , augments nitric oxide level decrease asthma exacerbation improve asthma care moderate severe asthma patient . This study randomize , placebo control trial subject receive either 3 month L-arginine supplementation placebo . The investigator monitor subject ' symptom , number asthma exacerbation , lung function . In addition , draw blood , obtain induced sputum sample measure exhale breath nitric oxide level monthly visit .</brief_summary>
	<brief_title>Effects L-arginine Supplementation Adults With Moderate Severe Asthma</brief_title>
	<detailed_description>The primary objective 3 month clinical study determine supplemental L-arginine decrease number asthma exacerbation patient severe asthma . L-arginine , natural amino acid , produce nitric oxide ( NO ) convert L-citrulline presence nitric oxide synthase enzyme . We others find NO protect allergic airway inflammation , airway hyperresponsiveness airway fibrosis various animal model . In addition , find arginase I expression correlate strongly lymphocyte eosinophil influx lung enzyme may regulate airway inflammatory response . Our central hypothesis L-arginine increase NO level lung decrease number acute exacerbation asthma . It may either decrease number Th2 lymphocytes down-regulating arginase I expression . Our specific aim , therefore , 1 . To test hypothesis , randomize , double-blinded , placebo control trial , 3 month L-arginine supplementation decrease number acute asthma exacerbation severe asthmatic patient , 2 . To determine whether L-arginine decrease ratio peripheral blood Th2 Th1 lymphocytes 3 . To determine whether L-arginine modulate serum arginase I/II level downstream product . Patients recruit primarily UC Davis Asthma Network ( UCAN ) clinic , focus care severe asthmatic , study perform UC Davis/VA General Clinical Research Center .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Moderate severe persistent asthma Subject stable asthma medication least one month If subject woman childbearing age , negative pregnancy test Less 18 yrs/ age Baseline Forced Expiratory Volume 1 second ( FEV1 ) &lt; 40 % predict Known suspect allergy Larginine Pregnant woman , nurse woman , woman actively try achieve pregnancy Current smoker Subjects 15 packyear history smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Airway Inflammation</keyword>
	<keyword>Moderate persistent asthma</keyword>
	<keyword>Severe Persistent Asthma</keyword>
</DOC>